Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2017 Nov 8

PMID 29109380

Citations 9

Authors

Malachy I Okeke

Arinze S Okoli

Diana Diaz

Collins Offor

Taiwo G Oludotun

Morten Tryland

Thomas Bohn

Ugo Moens

Affiliations

Soon will be listed here.

Abstract

Modified vaccinia virus Ankara (MVA) is the vector of choice for human and veterinary applications due to its strong safety profile and immunogenicity in vivo. The use of MVA and MVA-vectored vaccines against human and animal diseases must comply with regulatory requirements as they pertain to environmental risk assessment, particularly the characterization of potential adverse effects to humans, animals and the environment. MVA and recombinant MVA are widely believed to pose low or negligible risk to ecosystem health. However, key aspects of MVA biology require further research in order to provide data needed to evaluate the potential risks that may occur due to the use of MVA and MVA-vectored vaccines. The purpose of this paper is to identify knowledge gaps in the biology of MVA and recombinant MVA that are of relevance to its hazard characterization and discuss ongoing and future experiments aimed at providing data necessary to fill in the knowledge gaps. In addition, we presented arguments for the inclusion of uncertainty analysis and experimental investigation of verifiable worst-case scenarios in the environmental risk assessment of MVA and recombinant MVA. These will contribute to improved risk assessment of MVA and recombinant MVA vaccines.

Citing Articles

Multi-omics analysis reveals the dynamic interplay between Vero host chromatin structure and function during vaccinia virus infection.

Venu V, Roth C, Adikari S, Small E, Starkenburg S, Sanbonmatsu K Commun Biol. 2024; 7(1):721.

PMID: 38862613 PMC: 11166932. DOI: 10.1038/s42003-024-06389-x.

Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.

Diaz-Canova D, Moens U, Brinkmann A, Nitsche A, Okeke M Front Immunol. 2024; 15:1277447.

PMID: 38633245 PMC: 11021749. DOI: 10.3389/fimmu.2024.1277447.

Scanning the Horizon for Environmental Applications of Genetically Modified Viruses Reveals Challenges for Their Environmental Risk Assessment.

Eckerstorfer M, Dolezel M, Miklau M, Greiter A, Heissenberger A, Engelhard M Int J Mol Sci. 2024; 25(3).

PMID: 38338787 PMC: 10855828. DOI: 10.3390/ijms25031507.

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications.

Orlova O, Glazkova D, Bogoslovskaya E, Shipulin G, Yudin S Vaccines (Basel). 2022; 10(9).

PMID: 36146594 PMC: 9503770. DOI: 10.3390/vaccines10091516.

ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.

Damerval M, Fagnoni-Legat C, Louvrier A, Fischer S, Limat S, Clairet A Front Med (Lausanne). 2021; 8:713047.

PMID: 34926483 PMC: 8671638. DOI: 10.3389/fmed.2021.713047.

References

Wyatt L, Carroll M, Czerny C, Merchlinsky M, Sisler J, Moss B . Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology. 1998; 251(2):334-42. DOI: 10.1006/viro.1998.9397. View

Baur K, Brinkmann K, Schweneker M, Patzold J, Meisinger-Henschel C, Hermann J . Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol. 2010; 84(17):8743-52. PMC: 2919044. DOI: 10.1128/JVI.00604-10. View

Baldo A, van den Akker E, Bergmans H, Lim F, Pauwels K . General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr Gene Ther. 2013; 13(6):385-94. PMC: 3905712. DOI: 10.2174/15665232113136660005. View

Fleischauer C, Upton C, Victoria J, Jones G, Roper R . Genome sequence and comparative virulence of raccoonpox virus: the first North American poxvirus sequence. J Gen Virol. 2015; 96(9):2806-2821. DOI: 10.1099/vir.0.000202. View

Arnberg N . Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol. 2009; 19(3):165-78. DOI: 10.1002/rmv.612. View

Manuel E, Wang Z, Li Z, La Rosa C, Zhou W, Diamond D . Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology. 2010; 403(2):155-62. PMC: 2879446. DOI: 10.1016/j.virol.2010.04.015. View

Jordan I, Horn D, Oehmke S, Leendertz F, Sandig V . Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Res. 2009; 145(1):54-62. PMC: 7172177. DOI: 10.1016/j.virusres.2009.06.007. View

Sebastian S, Gilbert S . Recombinant modified vaccinia virus Ankara-based malaria vaccines. Expert Rev Vaccines. 2015; 15(1):91-103. PMC: 9491075. DOI: 10.1586/14760584.2016.1106319. View

Altenburg A, Kreijtz J, de Vries R, Song F, Fux R, Rimmelzwaan G . Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014; 6(7):2735-61. PMC: 4113791. DOI: 10.3390/v6072735. View

10.

Mauldin M, Antwerpen M, Emerson G, Li Y, Zoeller G, Carroll D . Cowpox virus: What's in a Name?. Viruses. 2017; 9(5). PMC: 5454414. DOI: 10.3390/v9050101. View

11.

Springer Y, Hsu C, Werle Z, Olson L, Cooper M, Castrodale L . Novel Orthopoxvirus Infection in an Alaska Resident. Clin Infect Dis. 2017; 64(12):1737-1741. PMC: 5447873. DOI: 10.1093/cid/cix219. View

12.

Ball L . High-frequency homologous recombination in vaccinia virus DNA. J Virol. 1987; 61(6):1788-95. PMC: 254181. DOI: 10.1128/JVI.61.6.1788-1795.1987. View

13.

Di Pilato M, Mejias-Perez E, Gomez C, Perdiguero B, Sorzano C, Esteban M . New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol. 2013; 94(Pt 12):2771-2776. DOI: 10.1099/vir.0.057299-0. View

14.

Holgado M, Falivene J, Maeto C, Amigo M, Pascutti M, Vecchione M . Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. Viruses. 2016; 8(5). PMC: 4885094. DOI: 10.3390/v8050139. View

15.

Block W, Upton C, McFadden G . Tumorigenic poxviruses: genomic organization of malignant rabbit virus, a recombinant between Shope fibroma virus and myxoma virus. Virology. 1985; 140(1):113-24. DOI: 10.1016/0042-6822(85)90450-7. View

16.

Staib C, Drexler I, Sutter G . Construction and isolation of recombinant MVA. Methods Mol Biol. 2004; 269:77-100. DOI: 10.1385/1-59259-789-0:077. View

17.

Chantrey J, Meyer H, Baxby D, Begon M, Bown K, Hazel S . Cowpox: reservoir hosts and geographic range. Epidemiol Infect. 1999; 122(3):455-60. PMC: 2809641. DOI: 10.1017/s0950268899002423. View

18.

Volz A, Sutter G . Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. Adv Virus Res. 2017; 97:187-243. PMC: 7112317. DOI: 10.1016/bs.aivir.2016.07.001. View

19.

Suter M, Meisinger-Henschel C, Tzatzaris M, Hulsemann V, Lukassen S, Wulff N . Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine. 2009; 27(52):7442-50. DOI: 10.1016/j.vaccine.2009.05.095. View

20.

Gallina L, Scagliarini A . Virucidal efficacy of common disinfectants against orf virus. Vet Rec. 2010; 166(23):725-6. DOI: 10.1136/vr.c3001. View